Stockreport

Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications

Kura Oncology, Inc.  (KURA) 
Last kura oncology, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.kuraoncology.com/investor-relations
PDF – Tipifarnib is a farnesyl transferase inhibitor that downregulates CXCL12 – – Gene expression of the exclusively farnesylated RHOE and PRICKLE2 proteins associated wit [Read more]